Oncologists expect Avastin Rxs to more than double: survey

Stephen McGuire

March 11 2008

A recent survey of oncologists indicates market share for Genentech's Avastin could more than double as a first-line and second-line ...

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.